{"id":575207,"date":"2026-02-04T00:00:00","date_gmt":"2026-02-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2022-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2022\/"},"modified":"2026-03-31T10:23:33","modified_gmt":"2026-03-31T10:23:33","slug":"unneon0010-2022-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2022-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2022\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck | Unmet Need | US\/EU | 2022"},"content":{"rendered":"<p>The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (SCCHN) patients in the first-line recurrent or metastatic setting. The approval of immune checkpoint inhibitors\u2014Keytruda (Merck &#038; Co.) and Opdivo (Bristol-Myers Squibb)\u2014in the first-line setting over the last decade has changed the treatment paradigm for recurrent or metastatic SCCHN patients as monotherapy and\/or in combination with platinum + 5-FU. However, there is a strong need for effective therapies in this patient setting. This report provides a detailed analysis of the factors that influence medical oncologists&#8217; prescribing decisions and reviews the unmet needs that novel therapies should confront.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals in medical oncologists\u2019 prescribing decisions for non-nasopharyngeal SCCHN?<\/li>\n<li>How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?<\/li>\n<li>What are the prevailing areas of unmet need and hidden opportunity that drug developers could leverage in the treatment of non-nasopharyngeal SCCHN?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical target product profile for non-nasopharyngeal SCCHN?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 33 European medical oncologists fielded in December 2021<\/p>\n<p><strong>Key companies:<\/strong> Merck &#038; Co., Bristol Myers Squibb, Eli Lilly<\/p>\n<p><strong>Key drugs:<\/strong> Erbitux, Keytruda, Opdivo<\/p>\n","protected":false},"template":"","class_list":["post-575207","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575207\/revisions"}],"predecessor-version":[{"id":575718,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575207\/revisions\/575718"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=575207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}